Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Jason Russ, Seeking Alpha (1/17/15)
"Inovio Pharmaceuticals Inc. is sitting on a fair amount of cash and can take some time to find a new partner for INO-5150 as well as new partners for some of its other candidates in the pipeline. . .the Phase 2 results for VGX-3100 go a long way to validating the company's SynCon vaccine concept as a whole. . .2014 was a successful year for Inovio, and it is one year closer to bringing a product to market."

Jason Kolbert, Maxim Group (1/6/15)
"In two published Phase 1 studies, administration of Inovio Pharmaceuticals Inc.'s Pennvax-B has been shown to generate high levels of antigen-specific CD8+ T-cells with proper functional characteristics. This ability to generate high level of activated CD8+ killer T-cells uniquely positions Pennvax as an important product candidate for preventing and treating HIV infections."

Jason Kolbert, Maxim Group (12/22/14)
"Inovio announced initiation of a Phase 1 trial of its novel DNA immunotherapy platform (SynCon) in patients at high risk of relapse of breast, lung and pancreatic cancers. The platform has been modified to target hTERT (INO-1400), an enzyme overexpressed in 85% of human cancers and believed to be a key player in cancer cells being immortal. . .the company's platform allows Inovio to swap out pieces ('plug and play') of DNA to target specific disease antigens. . .we believe that the platform technology has demonstrated measurable T-cell responses."

Zacks Equity Research (12/5/14)
"One stock that might be an intriguing choice for investors right now is Inovio Pharmaceuticals Inc. This security in the medical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. . .Inovio is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm's prospects in both the short and long term."

Jason Kolbert, Maxim Group (11/20/14)
"Inovio Pharmaceuticals Inc. announced its newest DNA-based cancer immunotherapy targeting melanoma induced a robust and broad immune response in animals and directed cancer-killing T-cells against tumors. The company now follows OncoSec Medical Inc. (spun out of Inovio) in going after melanoma but with a new, novel approach."

Jason Kolbert, Maxim Group (11/17/14)
"Inovio Pharmaceuticals Inc. and Roche Holding AG announced that their collaborative agreement for INO-5150 (prostate cancer) has been terminated. . .this change is not significant to our outlook for the company. . .Inovio plans to continue development of INO-5150, starting a Phase 1 trial in H1/15."

More Comments

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Inovio Pharmaceuticals Inc. Content